|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400089593 |
|
最近更新日期: Date of Last Refreshed on: |
2024-09-11 14:51:45 |
|
注册时间: Date of Registration: |
2024-09-11 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
新冠病毒(COVID-19)对男性生殖功能的影响 |
|
Public title: |
Effects of COVID-19 on male reproductive function |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新冠病毒(COVID-19)对男性生殖功能的影响 |
|
Scientific title: |
Effects of COVID-19 on male reproductive function |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵玉 |
研究负责人: |
赵晓丽 |
|
Applicant: |
Yu Zhao |
Study leader: |
Xiaoli Zhao |
|
申请注册联系人电话: Applicant telephone: |
+86 183 2270 3865 |
研究负责人电话: Study leader's telephone: |
+86 135 1209 2012 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhaoyu198865@126.com |
研究负责人电子邮件: Study leader's E-mail: |
zeruolove@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津市西青区昌凌路88号 |
研究负责人通讯地址: |
天津市西青区昌凌路88号 |
|
Applicant address: |
88 Changling Road, Xiqing District, Tianjin, China |
Study leader's address: |
88 Changling Road, Xiqing District, Tianjin, China |
|
申请注册联系人邮政编码: Applicant postcode: |
300000 |
研究负责人邮政编码: Study leader's postcode: |
300000 |
|
申请人所在单位: |
1.天津中医药大学第一附属医院 2.国家中医针灸临床医学研究中心 |
||
|
Applicant's institution: |
1. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine 2. National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion |
||
|
研究负责人所在单位: |
1.天津中医药大学第一附属医院 2.国家中医针灸临床医学研究中心 |
||
|
Affiliation of the Leader: |
1. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine 2. National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
TYLL2023[Z]字022 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津中医药大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-06-28 00:00:00 |
||
|
伦理委员会联系人: |
郑子琦 |
||
|
Contact Name of the ethic committee: |
Ziqi Zheng |
||
|
伦理委员会联系地址: |
天津市西青区昌凌路88号 |
||
|
Contact Address of the ethic committee: |
88 Changling Road, Xiqing District, Tianjin, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 22 2798 6258 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
天津中医药大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市西青区昌凌路88号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
88 Changling Road, Xiqing District, Tianjin, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China |
||||||||||||||||||||||
|
Target disease: |
Male infertility |
||||||||||||||||||||||
|
Target disease code: |
N46 |
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本研究旨在通过检测有生育愿望的男性感染SARS-CoV-2病毒后1-6个月内的精液质量变化,确定COVID-19对精子质量的影响,并评估完全恢复所需的时间。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study is designed to determine the impact of COVID-19 on sperm quality and evaluate the duration required for full recovery by examining semen quality variations within 1-6 months after SARS-CoV-2 virus infection among males with fertility aspirations. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 20 ~ 45岁男性; 2. 2022年4月至2023年1月期间曾就诊于我院生殖医学科; 3. 2022年12月至2023年1月期间曾感染新冠并已转阴(两次检验报告阴性); 4. 自愿参与,并同意签署知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Males aged 20 to 45; 2. Patients who visited our reproductive medicine department from April 2022 to January 2023; 3. Patients who were infected with COVID-19 from December 2022 to January 2023 and have recovered (two negative test reports); 4. Voluntary participation with agreement to sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 无新冠感染病史; 2. 重度少精症、弱精症、畸形精子症或无精症; 3. 曾接受输精管结扎术或前列腺手术; 4. 射精功能障碍; 5. 严重基础病(严重的心脑血管疾病、代谢性疾病及内分泌疾病); 6. 其他不育因素(隐睾,生殖器损伤或畸形,染色体异常); 7. 拒绝提供精液者; 8. 拒绝签署知情同意书者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. No history of COVID-19 infection; 2. Severe oligospermia, asthenospermia, teratospermia, or azoospermia; 3. Patients who have undergone vasectomy or prostate surgery; 4. Patients who have ejaculatory dysfunction; 5. Severe underlying diseases (severe cardiovascular and cerebrovascular diseases, metabolic diseases, and endocrine diseases); 6. Other infertility factors (cryptorchidism, genital injury or malformation, chromosomal abnormalities); 7. Individuals who refuse to provide semen samples; 8. Individuals who refuse to sign the informed consent form. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-04-01 00:00:00至 To 2023-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-01-15 00:00:00 至 To 2023-02-27 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
不适用 |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
实验数据在实验完成后6个月内公开在百度云网盘http://pan.baidu.com/share/manage |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The experimental data were publicly available on Baidu Cloud network disk within 6 months after the completion of the experiment. http://pan.baidu.com/share/manage |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集(精液参数、评分等)采用病例记录表进行相关参数的收集;数据管理采用REDCap软件 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
We used case record form to collect relevant parameters during data collection (semen parameters, scores, etc.); REDCap software was used for data management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |